Sapient leverages NULISA™ panels and assays to capture subtle changes in the low-abundance portion of the proteome, including cytokines, chemokines, and neuroinflammatory mediators.
Sapient is a Certified Service Provider for Alamar Biosciences’ NULISA™ assays on the ARGO® HT System. These assays complement and extend our mass spectrometry-based targeted proteomics services by enabling detection of hard-to-assay cytokines, chemokines, and neuroinflammatory mediators in biofluid samples.
The NULISA platform uses a proprietary sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ligation assays by over a thousand-fold to attomolar levels – allowing for highly quantitative measures of low-abundance proteins that are not amenable to mass spectrometry measure.
Detects 120+ biomarkers of CNS disease, including
neuro-specific proteins.
Through NULISA panels and assays, Sapient can provide highly quantitative measures of low-abundance proteins that are important modulators of immune processes. This complements our mass spectrometry-based (MS) proteomics in several ways by enabling:
Sapient is additionally working closely with Alamar to offer NULISAseq assays under regulated guidance, including CAP/CLIA and GCLP – further extending our multi-omics services for clinical development.
With attomolar sensitivity and 12 logs of dynamic range, the NULISAseq Inflammation Panel 250 profiles 250+ biomarkers of inflammation and immune response from a single 10μl sample, including low-abundance cytokines such as IL4, IL5, IL17, and IL33. It offers unmatched detectability of the most relevant cytokine and chemokine inflammation targets in blood-based and CSF biofluids.
Sapient also offers the the NULISAseq Inflammation Panel AQ for absolute quantification of 150+ of these key protein biomarkers. With 99% quantifiability in normal samples, this panel allows for detection of subtle changes related to disease progression or therapeutic response.
This panel provides best-in-class sensitivity and robust, multiplexed analysis of 120+ neuro-specific and inflammatory proteins associated with neurodegenerative disorders in plasma and CSF.
The panel includes important proteins such as p-tau217, GFAP, NfL, and alpha- synuclein and enables measure of changes in key inflammatory pathways, supporting protein biomarker discovery and validation for CNS diseases. Results are highly reproducible, with median CV <10%, even at multiplexing scale.
Learn about Alamar’s novel NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) and how it enables:
For questions or to discuss a specific project, we encourage you to book a time to talk to our scientific team.
"*" indicates required fields
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
